Please note, this OEL/ADE monograph also applies to cefovecin sodium (CAS RN 141195-77-9). Cefovecin sodium is indicated in the United States for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G) and for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida. The European authorization lists additional indications, such as urinary tract infections (E. coli and proteus. spp) and beta-hemolytic Streptococci and P. multocida infections in dogs, as well as urinary tract infections (E.coli), and for Fusobacterium spp., Bacteroides spp. and Prevotella oralis infections in cats.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL/ADE monograph for Cefovecin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.